HC Wainwright downgraded shares of Synlogic (NASDAQ:SYBX – Free Report) from a buy rating to a sell rating in a report released on Friday, MarketBeat.com reports. HC Wainwright also issued estimates for Synlogic’s FY2028 earnings at $7.05 EPS.
Several other equities analysts also recently commented on SYBX. Alliance Global Partners began coverage on shares of Synlogic in a research note on Monday, December 11th. They set a buy rating and a $30.00 price objective for the company. Chardan Capital cut shares of Synlogic from a buy rating to a neutral rating in a research note on Friday. Finally, SVB Leerink reissued a market perform rating on shares of Synlogic in a research note on Friday. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of Hold and an average price target of $65.00.
Synlogic Stock Down 2.8 %
Hedge Funds Weigh In On Synlogic
Institutional investors have recently bought and sold shares of the stock. Two Sigma Securities LLC purchased a new position in Synlogic during the first quarter valued at $27,000. WINTON GROUP Ltd bought a new stake in shares of Synlogic in the 3rd quarter worth about $35,000. Envestnet Asset Management Inc. lifted its holdings in shares of Synlogic by 273.4% in the 4th quarter. Envestnet Asset Management Inc. now owns 78,671 shares of the biotechnology company’s stock worth $60,000 after acquiring an additional 57,604 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Synlogic by 333.6% in the 4th quarter. Millennium Management LLC now owns 95,434 shares of the biotechnology company’s stock worth $73,000 after acquiring an additional 73,422 shares during the last quarter. Finally, Ensign Peak Advisors Inc bought a new stake in shares of Synlogic in the 1st quarter worth about $79,000. 47.18% of the stock is owned by hedge funds and other institutional investors.
Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase II clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.
- Five stocks we like better than Synlogic
- What is the NASDAQ Stock Exchange?
- 3 attractive stocks that insiders are buying
- Roth IRA Calculator: Calculate Your Potential Returns
- Alpha and Omega Semiconductor ready to bounce, DOJ cloud lifts
- The Most Important Warren Buffett Stock for Investors: His Own
- Wendy’s vs Shake Shack: Out with the new, in with the old?
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.